Supera-CBD

Supera-CBD is a novel, synthetic, non-toxic analog of cannabidiol (CBD) designed to have structural and functional similarity to plant-derived CBD but with significantly enhanced potency and selectivity. It acts as a highly potent agonist of the cannabinoid receptor type 2 (CB2), with approximately 8,000 times greater CB2 agonist activity than natural CBD and four-fold higher binding affinity for CB2. Unlike many cannabinoids, it has very low affinity for the cannabinoid receptor type 1 (CB1), minimizing psychoactive effects. Preclinical studies indicate that Supera-CBD demonstrates robust antidepressant, anti-anxiety, anti-inflammatory, anticonvulsant, and analgesic properties at low doses. Its mechanism is believed to involve selective activation of CB2 receptors as well as modulation of pain pathways such as TRPV1 channels involved in heat-related pain signaling. The compound is being developed primarily for neuropsychiatric disorders (such as depression and anxiety), chronic pain conditions (including inflammatory pain syndromes), addiction management, epilepsy/seizures, and potentially other indications where CBD shows therapeutic promise but requires improved efficacy or safety[1][2][3][4][5][6].

Brand names

Supera-CBD

Other names

synthetic cannabidiol analogsynthetic CBD analog